Therapy of metastatic bladder carcinoma

被引:12
作者
Iaffaioli, R. V. [1 ]
Milano, A. [1 ]
Caponigro, F. [1 ]
机构
[1] Natl Tumor Inst Naples, Fdn G Pascale, I-80131 Naples, Italy
关键词
biologic therapies; chemotherapy; cisplatin; metastatic bladder carcinoma; M-VAC;
D O I
10.1093/annonc/mdm246
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The methotrexate, vinblastine, doxorubicin, cisplatin (M-VAC) regimen has been considered as standard treatment of metastatic bladder carcinoma till recent years. The superiority of M-VAC both to cisplatin alone and to another cisplatin combination regimen has been demonstrated in randomized studies. During the last years, the use of gemcitabine in metastatic bladder carcinoma has considerably increased, mainly in combination with cisplatin (CG). A phase III trial comparing VI-VAC and CG demonstrated similar activity and less toxicity for CG, which has now become the new standard of care for patients with metastatic bladder carcinoma. The substitution of cisplatin with carboplatin, the combination of platinum and taxanes, and the addition of a third drug to basal CG combination represent possible ways to improve outcome. Among the novel cytotoxic compounds, pernetrexed has raised interest, since a phase 11 second-line study showed a 28% response rate with a manageable toxicity profile. Vinflunine is a novel antitubulin agent with a relevant clinical activity in pretreated metastatic bladder carcinoma (118% response rate, 6.6 months median survival). Novel biologic compounds (in particular drugs targeting epidermal growth factor receptor) are being tested in metastatic bladder carcinoma also and much effort is being pursued in understanding the determinants of tumor response. Crucial mutations to which the tumor becomes addicted have to be discovered so that more effective and specific drugs or combinations can be delivered.
引用
收藏
页码:153 / 156
页数:4
相关论文
共 38 条
[1]   The proteasome: structure, function, and role in the cell [J].
Adams, J .
CANCER TREATMENT REVIEWS, 2003, 29 :3-9
[2]   Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: A multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group [J].
Bamias, A ;
Aravantinos, G ;
Deliveliotis, C ;
Bafaloukos, D ;
Kalofonos, C ;
Xiros, N ;
Zervas, A ;
Mitropoulos, D ;
Samantas, E ;
Pectasides, D ;
Papakostas, P ;
Gika, D ;
Kourousis, C ;
Koutras, A ;
Papadimitriou, C ;
Bamias, C ;
Kosmidis, P ;
Dimopoulos, MA .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (02) :220-228
[3]   Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: Implications for therapy [J].
Blehm, Kelly N. ;
Spiess, Philippe E. ;
Bondaruk, Jolanta E. ;
Dujka, Melanie E. ;
Villares, Gabriel J. ;
Zhao, Yi-jue ;
Bogler, Oliver ;
Aldape, Kenneth D. ;
Grossman, H. Barton ;
Adam, Liana ;
McConkey, David J. ;
Czerniak, Bogdan A. ;
Dinney, Colin P. ;
Bar-Eli, Menashe .
CLINICAL CANCER RESEARCH, 2006, 12 (15) :4671-4677
[4]   M-VAC (METHOTREXATE, VINBLASTINE, DOXORUBICIN AND CISPLATIN) FOR ADVANCED-CARCINOMA OF THE BLADDER - THE FRENCH FEDERATION OF CANCER CENTERS EXPERIENCE [J].
BOUTANLAROZE, A ;
MAHJOUBI, M ;
DROZ, JP ;
CHARROT, P ;
FARGEOT, P ;
KERBRAT, P ;
CATY, A ;
VOISIN, PM ;
SPIELMANN, M ;
REY, A ;
GIRAUD, B .
EUROPEAN JOURNAL OF CANCER, 1991, 27 (12) :1690-1694
[5]   Epidermal growth factor receptor as a major anticancer drug target [J].
Caponigro, Francesco ;
Milano, Amalia ;
Ottaiano, Alessandro ;
Iaffaioli, Rosario Vincenzo .
EXPERT OPINION ON THERAPEUTIC TARGETS, 2006, 10 (06) :877-888
[6]  
CARTENI G, 2003, P AM SOC CLIN ONCOL, V22
[7]  
*CLIN TRIALS GOV, 2006, INF CLIN TRIALS HUM
[8]   A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen [J].
Culine, S. ;
Theodore, C. ;
De Santis, M. ;
Bui, B. ;
Demkow, T. ;
Lorenz, J. ;
Rolland, F. ;
Delgado, F. -M. ;
Longerey, B. ;
James, N. .
BRITISH JOURNAL OF CANCER, 2006, 94 (10) :1395-1401
[9]   Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer [J].
Dominguez-Escrig, JL ;
Kelly, JD ;
Neal, DE ;
King, SM ;
Davies, BR .
CLINICAL CANCER RESEARCH, 2004, 10 (14) :4874-4884
[10]   Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium - A trial of the eastern cooperative oncology group [J].
Dreicer, R ;
Manola, J ;
Roth, BJ ;
See, WA ;
Kuross, S ;
Edelman, MJ ;
Hudes, GR ;
Wilding, G .
CANCER, 2004, 100 (08) :1639-1645